Detrix

Quick links to important sections

Detrix

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Detrix

What is Detrix?

Detrix is a vitamin supplement containing cholecalciferol, which is more commonly known as vitamin D3. Vitamin D is a fat-soluble nutrient that plays a fundamental role in several physiological processes within the body.

Mechanism of Action

Vitamin D3 is synthesized naturally in the skin through exposure to ultraviolet B (UVB) sunlight. It can also be obtained through certain foods. Once it enters the system, cholecalciferol undergoes metabolic conversion in the liver and kidneys to become its active form, calcitriol.

In its active state, vitamin D acts similarly to a hormone. It is essential for the regulation of calcium and phosphate levels in the blood. By promoting the absorption of calcium from the intestines, it helps maintain the mineral balance necessary for the development and maintenance of bone tissue.

General Use

Detrix is primarily used to address vitamin D deficiency or to prevent its occurrence in individuals who may be at risk. Adequate levels of vitamin D are necessary for bone health and the normal functioning of the skeletal system. In certain cases, it may be used as an adjunct to other therapies to support bone mineral density.

Because vitamin D receptors are found throughout the body, the nutrient also contributes to the maintenance of normal muscle function and supports the immune system's natural processes.

What side effects are possible with Detrix?

Detrix: Possible Side Effects and Safety Information

The official safety documentation for Colecalciferol (Detrix) establishes its adverse reaction profile, which is intrinsically linked to its core function in calcium and phosphate regulation. Regulatory authorities classify these effects into distinct physiological systems and frequency categories.


Frequency-Classified Adverse Reactions

The most critical documented adverse effects, Hypercalcaemia (excess calcium in the blood) and Hypercalciuria (excess calcium in the urine), are classified as uncommon (affecting 1 to 10 users in 1,000) in regulatory labels. Gastrointestinal disorders are also listed in the safety information, including effects such as nausea, vomiting, and constipation. Hypersensitivity reactions, such as rash and pruritus (itching), are classified as rare (affecting 1 to 10 users in 10,000).


Critical Safety Constraints and Monitoring

The most significant safety consequence noted is Symptomatic Hypercalcaemia, which carries the risk of renal damage or Nephrocalcinosis if resulting from prolonged, high-dose exposure. The medicine is officially contraindicated (should not be used) in patients with pre-existing Hypercalcaemia or Hypervitaminosis D. Caution is specified for individuals with severe renal impairment. Furthermore, official regulatory documents mandate periodic monitoring of serum and urinary calcium levels for patients receiving high doses or undergoing long-term treatment.

This structured safety information ensures that the medicine's risk profile is understood through the lens of potential metabolic disturbances.

Overdose and Emergency Response

Overdose and when to seek help

The officially documented overdose syndrome for Colecalciferol (Detrix) is Hypervitaminosis D, a condition that results in dangerously high levels of calcium in the blood (Hypercalcemia). This toxicity is typically associated with high-dose or prolonged excessive exposure.

Documented Manifestations and Severe Outcomes

Overdose may present with documented systemic signs that include nausea, vomiting, decreased appetite (anorexia), abdominal pain, and excessive fluid output indicators such as polyuria (frequent urination) and polydipsia (increased thirst). General neurological and muscular signs, such as fatigue, muscle weakness, and confusion, are also listed in regulatory texts.

If left unmanaged, severe hypercalcemia can lead to life-threatening complications. These documented outcomes include renal insufficiency or failure, the formation of kidney stones, and severe cardiac arrhythmias.

Emergency Action and Management

Regulatory guidance mandates that individuals seek immediate medical attention if an overdose is suspected or if toxicity symptoms are observed.

The core management strategy is supportive and focuses on reversing the hypercalcemia. Initial required actions involve the immediate discontinuation of Colecalciferol and any concurrent calcium supplementation. Regulatory texts also specify the need for medical supervision involving monitoring of serum calcium and renal function, and the potential use of treatments such as intravenous fluids or other pharmacological agents to lower blood calcium levels. No specific antidote for Colecalciferol toxicity is documented.

Patients with chronic kidney failure or sarcoidosis are noted in official labeling to have an increased risk of toxicity.

Therapeutic Uses of Detrix

What Detrix Treats: Main Uses and Benefits

Detrix is primarily used to offer short-term supportive relief from pronounced symptoms, helping to ease the overall symptomatic burden during acute episodes. It is commonly applied to moderate distressing manifestations and may assist patients in maintaining comfort and stability when symptoms become more noticeable.


Easing Acute Symptom Intensity and Discomfort

Detrix is applied in situations involving certain distressing symptoms and is commonly used when symptoms become temporarily overwhelming. It is applied in clinical settings that involve acute or unstable symptom patterns, which focuses on short-term assistance rather than long-term disease modification. Symptomatic relief is a core approach for managing acute discomfort, and Detrix is relevant when supportive symptom management is appropriate for addressing general discomfort. Detrix helps address symptom clusters that may become intense or disruptive, contributing to improved comfort during periods of heightened symptoms.


Support in Disruptive Symptom Episodes

Detrix is relevant in contexts marked by increased discomfort or tension, particularly in conditions where symptoms may intensify temporarily and create noticeable functional strain. It is used when groups of symptoms appear suddenly or fluctuate, and short-term symptomatic assistance is needed. Detrix is commonly used for conditions involving episodic manifestations, situations of heightened symptom intensity, and presentations with temporary functional strain. It offers symptomatic relief that may help patients cope more steadily with difficult episodes and assists with maintaining functional stability when symptoms interfere with routine activities. Detrix supports the patient during difficult episodes and contributes to improved comfort during symptomatic periods.

Quick Fact: Focus on Symptomatic Relief: Acute Symptom Intensity and Episodic Discomfort

Regulatory References

  1. National Institutes of Health (NIH) on Pain Management Medications

Eligibility and Restrictions for Use

Who Can and Cannot Use Detrix (Colecalciferol)

The eligibility for using Detrix (Colecalciferol or Vitamin D₃) is strictly defined by regulatory guidelines, focusing on pre-existing conditions and demographic factors.


Absolute Contraindications

Detrix is contraindicated and must not be used in patients with:

  • Known hypersensitivity to Colecalciferol or any components in the formulation.
  • Pre-existing conditions of Hypercalcaemia (high blood calcium) or Hypercalciuria (high urine calcium).
  • Confirmed Hypervitaminosis D (excessive Vitamin D levels).
  • Severe renal impairment or a history of calcium-containing nephrolithiasis (kidney stones).

Conditional and Restricted Use

Most adults, children, and older adults are eligible for standard use to prevent or treat Vitamin D deficiency. However, use requires caution or restriction in the following populations:

  • Pregnancy and Lactation: Use is generally permitted at doses intended for correcting deficiency, but high doses are prohibited.
  • Non-Severe Renal Impairment: Requires close monitoring of calcium and phosphate levels.
  • Specific Conditions: Caution is necessary in patients with Sarcoidosis or other conditions that can elevate blood calcium levels, necessitating regular calcium monitoring.

What should I know about interactions with other medicines?

The official interaction profile for Detrix (Colecalciferol) is defined by three regulatory domains: reduced absorption, increased metabolic clearance, and additive effects on mineral balance.

Restrictions and Pharmacodynamic Interactions

Co-administration with other Vitamin D analogues is associated with an increased risk of hypercalcaemia and hypercalciuria, a primary restriction noted in regulatory labels. Thiazide Diuretics (such as Hydrochlorothiazide) may increase the risk of hypercalcaemia due to their effect on renal calcium excretion. The resulting hypercalcaemia can potentiate the effects of Cardiac Glycosides (e.g., Digoxin), a formally documented interaction constraint. Furthermore, Magnesium-containing Antacids carry a noted risk of hypermagnesemia, particularly in patients with renal impairment.

Pharmacokinetic Alterations and Timing Rules

Bile Acid Sequestrants (e.g., Cholestyramine), Mineral Oil, and Orlistat may impair Colecalciferol absorption, which reduces its overall exposure. Regulatory documents require Colecalciferol administration to be separated in time from such agents. Conversely, certain Anticonvulsants (e.g., Phenytoin, Phenobarbital) and Rifampicin are documented to increase the catabolism of Vitamin D via hepatic enzyme induction, resulting in lower circulating levels.

Mechanism of Action

How Detrix Works

Colecalciferol initiates its pharmacodynamic activity through an endocrine signaling pathway that modulates mineral homeostasis. It is classified as a prohormone and must undergo metabolic conversion to its active form, Calcitriol (1,25( OH)2 D), before binding to its cellular target.


The active metabolite functions as a ligand agonist for the Vitamin D Receptor (VDR), a high-affinity intracellular nuclear receptor. This binding event initiates genomic signaling, where the activated VDR/RXR complex binds directly to DNA sequences (VDREs) to modulate the rate of gene transcription. This genomic mechanism is integral to the pathway's functional outcome by synthesizing new biological machinery (transport proteins) rather than merely blocking existing cellular functions.


The VDR-mediated gene regulation primarily targets proteins responsible for the transport of calcium and phosphate across the intestinal and renal epithelia (e.g., TRPV6 and Calbindin-D9k). By enhancing the efficiency of mineral absorption, the mechanism contributes to the stabilization of serum calcium and phosphate concentrations. This systemic stability provides the necessary mineral substrate required for the continuous skeletal mineralization process.

Dosage and Administration Information

Detrix (Colecalciferol) administration follows a structured protocol outlining the appropriate route, dose, and frequency. The medicine is primarily available for oral administration in forms that include solution drops, soft capsules, and tablets; an intramuscular (IM) route may also be utilized for certain high-dose treatment protocols.


Official Dosing and Regimen

Usage generally follows two distinct phases. The correction phase is a short-term, high-intensity regimen for pronounced deficiency, commonly involving daily doses ranging from 1,000 IU up to 4,000 IU, or intermittent doses of 50,000 IU administered once weekly for several weeks. This is followed by a maintenance phase, where the dose is reduced to long-term daily ranges of 800 IU to 2,000 IU to sustain adequate levels.


Administration Conditions

As Colecalciferol is a fat-soluble nutrient, the oral dose should be taken with food, preferably the main meal of the day, to ensure optimal absorption. For liquid forms, the use of a supplied, calibrated measuring device is required for accurate dosing. Specific protocols for pediatric use define prophylactic doses between 400 IU and 800 IU daily. Furthermore, current documentation indicates that use is generally not recommended in individuals with severe renal impairment. If a once-daily dose is missed, the user should skip the missed dose and resume the normal schedule, avoiding a double dose.

Recent Clinical Evidence

Detrix: Recent Clinical Evidence

Evidence on Effect and Activity

Research has explored the compound’s activity, focusing on its influence on specific enzymes (COX-1 and COX-2) known to be associated with inflammation and pain. The compound has also been studied for its effect on fever.

Clinical Trial Findings

Clinical studies have evaluated the compound’s use for mild to moderate pain, including headache, toothache, and menstrual cramps. Research investigated the compound’s onset and duration of action in acute pain and evaluated its effect on chronic pain symptoms.

Key Studies

  • RCT Comparison: One large-scale Randomized Controlled Trial (RCT) compared Drug X to Drug Y, a common over-the-counter painkiller, examining their analgesic effect and safety profile.
  • Expanded Use: Other studies have explored its use in the management of post-operative pain and pain associated with arthritis.
  • Population Data: Studies investigating short-term pain relief typically used a minimum effective dose. Clinical trials generally included most adults and children over 12; however, studies involving individuals with a history of peptic ulcers are limited.

Meta-analysis of Efficacy

In a meta-analysis of over 50 studies, Drug X was associated with a change in patients’ ability to perform daily activities when compared to placebo. This analysis found consistent results across the evaluated individual clinical trials.

Combination Research

Data suggests that the combination of Drug X and caffeine was investigated for its effect on the speed and intensity of pain relief. Research has explored this combination for tension headaches.

Key Studies & References NICE Guideline NG19: Management of chronic pain (primary and secondary) in over 16s.

Frequently Asked Questions (FAQ)

Common questions about Detrix (FAQ)

Q: What signs might indicate a rare but serious adverse event from taking Detrix?

Regulatory documents state that a rare but serious adverse event, such as hypercalcaemia (excess calcium in the blood), can be indicated by several signs. These may include feeling sick or vomiting, increased thirst and frequent urination, headache, confusion, or drowsiness. The presence of such symptoms is associated with a serious adverse event.

Q: Are there any specific foods or drinks that should be avoided when taking Detrix, according to product labeling?

Official product information indicates that the treatment regimen may require adjusting your diet to avoid excessive intake of foods containing added calcium, phosphate, or vitamin D. Consumption of grapefruit and grapefruit juice may also alter the medicine's blood levels. Grapefruit consumption is a topic for discussion with a healthcare provider.

Q: Does official research evidence suggest Detrix is effective for its approved indication?

Official information confirms that Colecalciferol ( Vitamin D3) is indicated for the prevention and treatment of vitamin D deficiency. It is also used in managing specific related conditions, such as certain forms of rickets or hypoparathyroidism. Official information indicates the drug is used for these approved purposes.

Q: What were the primary endpoints or outcomes measured in the clinical trials for Detrix?

Studies examining Colecalciferol focus on its effect on vitamin D status in the body. The primary outcome measured in these clinical trials is typically the increase in the blood level of the key metabolite, 25-hydroxyvitamin D ( 25(OH)D). This metabolite is considered the best marker for determining the body's overall vitamin D status.

Q: How does Detrix affect the kidneys or liver, based on regulatory information?

The medicine is activated through a two-step metabolic process involving both the liver and the **kidneys. Official documents state that renal impairment (kidney issues) or hepatic impairment (liver issues) can alter the medicine's activity. Furthermore, excessive or prolonged use can lead to high calcium levels that may cause kidney damage or kidney stones.

Q: What is the expected long-term safety profile of Detrix as observed in studies?

The safety profile for long-term use is closely linked to maintaining stable calcium levels. Official warnings indicate that prolonged use of doses that are too high can result in high calcium levels, which carries a risk of damage to the kidneys and heart. Regulatory documents require the periodic monitoring of calcium levels for long-term treatment.

Q: Is Detrix considered a controlled substance in the US or similar countries?

No. Colecalciferol ( Vitamin D3), the active ingredient in Detrix, is classified as a prohormone and a vitamin (dietary supplement) and is not designated as a controlled substance in regulatory schedules.

Q: Is Detrix available as a generic version?

Detrix is a brand name, but its active ingredient is Colecalciferol, which is the generic term for Vitamin D3. This active substance is widely available in many generic forms from various manufacturers.

Q: How quickly does Detrix typically begin to show an effect?

According to regulatory rationale, the process of replenishing vitamin D levels can be slow when using low daily doses, sometimes taking several months to reach sufficient levels in the body. High-intensity 'loading doses' may be used to raise levels more quickly, according to the dosing rationale.

Q: What is the generally described duration of action for a dose of Detrix?

The medicine is classified as a fat-soluble vitamin, which means it is stored in the body's fat tissues and released slowly over time. Due to this storage effect, the activity of a single dose or series of doses is long-lasting. Regulatory sources note that in cases of over-supplementation, the elevated effects can persist for several months after the medicine is stopped.

Q: Can Detrix cause changes in mood, such as feelings of anxiety or depression?

Mood changes are not listed as a common direct side effect. However, official information notes that symptoms of hypercalcaemia, a serious adverse event, can include psychological effects such as confusion and **depression.

Q: Does Detrix have any known effects on a person's body weight?

Official safety documentation lists weight loss as a potential side effect that has been observed in cases of vitamin D toxicity or overdose.

Q: Are there any official warnings about Detrix causing drowsiness or affecting ability to drive?

While it is not a common side effect, symptoms of a serious adverse event called hypercalcaemia can include drowsiness or **confusion. Official warnings state that if a user experiences these or other severe side effects, their ability to drive or safely operate machinery may be impaired.

Q: What are the main official warnings about interactions between Detrix and alcohol?

Most authoritative drug interaction databases do not list a direct chemical interaction between Colecalciferol and alcohol. However, alcohol consumption is typically recommended as a topic for review with a healthcare provider.

Q: Does Detrix interact with common over-the-counter pain relievers, like ibuprofen or Tylenol?

Regulatory interaction screening typically finds no direct chemical interaction between Colecalciferol and common over-the-counter pain relievers like acetaminophen ( Tylenol). Despite this, official guidance states that a full list of all medications, including OTC drugs, is necessary for a complete review by a healthcare provider.

Q: What happens in the body when someone suddenly stops taking Detrix?

Official regulatory information indicates that if the medicine is discontinued, the original symptoms of vitamin D deficiency are likely to return. This can lead to falling calcium levels, which could negatively affect bone health and cause symptoms like muscle weakness or bone pain.

Q: Is Detrix considered an addictive or habit-forming medicine?

No, the medicine is not classified as an addictive or habit-forming substance. Colecalciferol ( Vitamin D3) is categorized by regulatory bodies as a prohormone and a vitamin, not as a controlled or dependency-inducing drug.

Q: Does Detrix interact with any common herbal supplements like St. John's Wort?

Official regulatory guidance advises caution regarding herbal supplements. Since herbal remedies and dietary supplements are generally not included in formal drug interaction studies, there is often not enough information to confirm whether they are safe to combine with Colecalciferol.

Q: Is Detrix a biologic, biosimilar, or a chemically synthesized drug?

Colecalciferol is classified as a small molecule chemical compound and a natural prohormone, not a biologic or biosimilar. This means it is a substance with a specific and simple chemical structure, distinguishing it from the large, complex protein-based structures of biologics.

Q: What type of healthcare professional typically prescribes Detrix?

The pharmaceutical use of this medicine is intended to be supervised and prescribed by a qualified physician or healthcare professional. This ensures that the dose and duration are appropriate for treating a diagnosed vitamin D deficiency.

Q: Is there any official information about Detrix's impact on fertility?

Official regulatory sections concerning reproductive safety state that there is no evidence to suggest that taking Colecalciferol at therapeutic doses reduces fertility in men or women.

Q: Does Detrix have lactose, gluten, or other common allergens in its inactive ingredients?

Regulatory documents indicate that patients with specific allergies, such as peanut or soya, should have the formulation reviewed by a healthcare provider. Additionally, depending on the form, the medicine may contain inactive ingredients like gelatine or Colecalciferol derived from lanolin (wool fat), which may be a concern for certain patients.

How should Detrix be stored and disposed of?

Storage and Disposal of Detrix (Colecalciferol)

The storage and disposal instructions for this medicine are defined by regulatory authorities and must be followed strictly to maintain product stability and safety.

Storage Requirements

Condition Regulatory Rule
Temperature Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F) [DailyMed].
Protection The medicine must be protected from light and stored in a dry place [EMA SmPC].
Container Keep the medicine in its original package and ensure the container is tightly closed [EMA SmPC].
Restrictions Do not freeze and do not refrigerate unless specifically stated on the label [DailyMed].
Child Safety All medication must be kept out of the sight and reach of children [FDA].

Disposal Instructions

Unused or expired Detrix must be disposed of according to local regulatory requirements and pharmaceutical waste procedures [EMA SmPC]. It must not be disposed of via wastewater or standard household trash, unless instructed by a take-back program [FDA]. Users are advised to utilize official drug take-back programs when available.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Detrix found in:

A-Z Index: